Compare Repligen Corporation Common Stock (RGEN) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs S&P500 ETF — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while S&P500 ETF trades at $766.8 (market cap $821.11B). The key difference: S&P500 ETF is far larger — about 73.7× Repligen Corporation Common Stock's market cap, and S&P500 ETF is more actively traded (25,825,560 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and S&P500 ETF for 206 Days on average.
| RGEN | SPY | |
|---|---|---|
Market Cap | $11.14B | $821.11B |
Volume | 1,259,263 | 25,825,560 |
Sector | Health | — |
52-Week High | $194.57 | $779.14 |
52-Week Low | $102.87 | $631.99 |
Typical Hold Time | 0 Days | 206 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SPY (SPDR S&P 500 ETF Trust) trades at $778.05, showing minimal daily movement with a slight decline of -0.02 (-0.0%). Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains its position as the primary S&P 500 tracking fund with upcoming dividend distribution scheduled for October 2026.
The ETF's outlook remains tied to broader market performance with Wall Street monitoring earnings growth projections. Key risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated market valuations. Current technical strength suggests near-term stability, but macroeconomic factors could drive volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
